Profile

Graeme Kay
Title: Dr
First Name: Graeme
Surname: Kay
Position: Teaching Group Leader
Telephone: +44 (0) 1224 262548
Email:
Linkedin: LinkedIn Icon http://uk.linkedin.com/pub/graeme-kay/16/367/724
ORCID: ORCID Icon http://orcid.org/0000-0003-4792-1598

Connect via ResearchGateConnect via LinkedInDr Kay is a teaching group leader at the School of Pharmacy and Life Sciences.

His key research interests lie in the areas of medicinal chemistry, organic chemistry and pharmaceutical chemistry.

Duties and Responsibilities

  • Teaching group leader within the School of Pharmacy and Life Sciences.
  • Member of the School Ethics Committee, School Academic Board, MPharm Assessment Board

Academic Background

Dr Kay joined the University in January 2005 after a brief spell in industry as a development chemist. Previous to that he was employed at Edinburgh Napier University as a researcher in organo-medicinal chemistry. He was educated at Edinburgh Napier University where he gained a BSc (Hons) degree in Applied Chemistry and a PhD in Anti-Cancer Medicinal Chemistry.

Dr Kay's professional body memberships include FRSC, CCHEM, MAPS, MCSFS and SRPharmS.

Research Interests

Dr Kay's research interests lie in the areas of medicinal, organic and pharmaceutical chemistry. His key research skills include:

  • Organo-medicinal chemistry,
  • Mass spectrometry, and
  • NMR and IR spectroscopy.

Specialist research facilities available to Dr Kay include the medicinal chemistry research laboratory and the NMR facility.

Current Research

Dr Kay's current research in the field of drug development include:

  • Design and synthesis of novel prodrugs for the treatment of nephropathic cystinosis
  • Formulation of cysteamine as a dosage form for rectal delivery
  • Formulation of cysteamine as a dosage form for ophthalmic delivery
  • Design and synthesis of amino-substituted anthraquinones as potential anti-cancer agents

Funding

Dr Kay has received over £230,000 in funded research. Awards include:

  • SPARKS, The Children's Medical Research Charity. 2011, Research project, £101,544.
  • Institute for Health & Welfare Research, RGU. 2010, PhD studentship, £50,000.
  • Institute for Health & Welfare Research, RGU. Co-applicant (with Prof. Donald Cairns (PI), Dr Phil Cox & Dr Emma Hector), 2009, PhD studentship, £50,000.
  • The Cystinosis Foundation UK. 2008, PhD Funding, £26,355.
  • Cystinosis Foundation of Ireland. Co-applicant (with Prof. Donald Cairns (PI), 2008, Research project, £65,000.
  • Tenovus Scotland. 2007. Consumable funding, £5325 .
  • Cystinosis Research Network USA. Co-applicant (with Dr Rachel Knot (PI) & Prof. Donald Cairns), 2007, Research project, £35,000.

Publications

  1. B. McKenzie, G. Kay*, K. H. Matthews, R. M. Knott and D. Cairns. The hen's egg chorioallantoic membrane (HET-CAM) test to predict the ophthalmic irritation potential of a cysteamine-containing gel: Quantification using Photoshop® and ImageJ. International Journal of Pharmaceutics 490 (2015) 1–8. doi:10.1016/j.ijpharm.2015.05.023
  2. McKenzie B, Kay G, Matthews KH, Knott RM and Cairns D. Preformulation of cysteamine gels for treatment of the ophthalmic complications in cystinosis. International Journal of Pharmaceutics. 2016; 515, 1-2, p. 575-582. doi:10.1016/j.ijpharm.2016.10.044
  3. B.McKenzie, G. Kay. Eye gels for ophthalmic delivery. Expert Rev. Ophthalmol. Early online, 1–7 (2015). ISSN 1746-9899. doi:10.1586/17469899.2015.1015993
  4. A. Benylles, D. Cairns, P. J. Cox and G. Kay. Three salts from the reactions of cysteamine and cystamine with L-(+)-tartaric acid. Acta Crystallographica Section C, Crystal Structure Communications. Volume 69, Part 6 (June 2013). doi:10.1107/S0108270113012377
  5. B. E. Buchan, G. Kay, K. H. Matthews and D. Cairns. Suppository formulations as a potential treatment for Nephropathic Cystinosis. Journal of Pharmaceutical Sciences, Volume 101, Issue 10, pages 3729–3738, October 2012. doi:10.1002/jps.23246
  6. Omran, Z.; Kay, G.; Moloney, K. A.; Benylles. A.; Knott, R. M.; Cairns, D. Bioorganic & Medicinal Chemistry. Synthesis and in vitro evaluation of novel pro-drugs for the treatment of nephropathic cystinosis. 2011, doi:10.1016/j.bmc.2011.04.022
  7. Omran, Z.; Kay, G.; Hector, E. E, Knott, R. M.; Cairns, D.Folate pro-drug of cystamine as an enhanced treatment for nephropathic cystinosis. Bioorganic & Medicinal Chemistry Letters. 2011, 21, 8, 2502-4. doi:10.1016/j.bmcl.2011.02.048
  8. Omran, Z.; Kay, G.; Di Salvo, A.,Knott, R. M.; Cairns, D. Bioorganic & Medicinal Chemistry Letters. PEGylated derivatives of cystamine as enhanced treatments for nephropathic cystinosis. 2011, 21, 45. doi:10.1016/j.bmcl.2010.11.085
  9. G. Kay, Z. Omran, A. Di Salvo, R.C. Mulrooney, M. MacKay, E. Hector, T. Mullen, R.M. Knott, D. Cairns. Journal of Pharmacy and Pharmacology, Supplement. Synthesis and biological evaluation of pegylated cysteamine compounds for the treatment of cystinosis.2010; 62, 10, p. 1378, doi:10.1111/j.2042-7158.2010.01178.x
  10. B. E. Buchan, G. Kay, K. H. Matthews, M. Ramsey and D. Cairns. Journal of Pharmacy and Pharmacology, Supplement. The formulation and evaluation of a dry powder for pulmonary delivery in cystinosis. 2010; 62, 10, p. 1308, doi:10.1111/j.2042-7158.2010.01178.x
  11. B. E. Buchan, G. Kay*, K. H. Matthews and D. Cairns. International Journal of Pharmaceutics. Gel formulations for treatment of the ophthalmic complications in cystinosis.. Volume 392, Issues 1-2, 192-197. doi:10.1016/j.ijpharm.2010.03.065
  12. B. McCaughan, G. Kay*, A. Di Salvo, P.J. Cox, D. Cairns. Journal of Chemical Crystallography, Synthesis, characterization, photo-physical evaluation and crystal structure of 2-methoxy-1-methylquinolinium tetrafluoroborate, a potentially selective agent for the quantitative measurement of biologically relevant thiols. 2009. doi:10.1007/s10870-009-9670-5
  13. B. E. Buchan, G. Kay, K. H. Matthews and D. Cairns. Journal of Pharmacy and Pharmacology, Supplement. Formulation and Evaluation of Cysteamine for Ophthalmic Delivery. 2009; 61, 98, p. 73 doi:10.1211/002235709789037062
  14. M. Byres, P.J. Cox, G. Kay and E. Dixon . Supramolecular structures of six adenine-carboxylic acid complexes" CrystEngComm., 11, 135-142, 2009 doi:10.1039/b811243f
  15. B. E. Buchan, G. Kay, K. H. Matthews and D. Cairns. Journal of Pharmacy and Pharmacology, Supplement. Formulation and evaluation of novel dosage forms of cysteamine for the potential treatment of cystinosis. 2008; 139. p. 55. doi:10.1211/002235708785623345
  16. McCaughan, B.; Kay, G.; Knott, R. M.; Cairns, D. Bioorganic & Medicinal Chemistry Letters. A potential new prodrug for the treatment of cystinosis: Design, synthesis and in-vitro evaluation. 2008, 18, 1716. doi:10.1016/j.bmcl.2008.01.039
  17. Cairns D, Benylles A, McCaughan B, Kay G. Journal of Pharmacy and Pharmacology, Supplement. Molecular modelling of the interactions between cysteamine and cystamine prodrugs and b cyclodextrin. 2007; 59(4). p. 49.
  18. Kay,G, Melville M, McCaughan B, Warasiha B, Mincher, D.J. Journal of Pharmacy and Pharmacology, Supplement. Design, synthesis and biological evaluation of novel DNA binding agents. 2007; 59(4). p. 8.
  19. Kay G, Cairns D, McCaughan B, Warasiha, B. Journal of Pharmacy and Pharmacology, Supplement. The design, synthesis and biological evaluation of novel prodrugs for the treatment of cystinosis. 2007; 59(4). p. 7.513
  20. Design of the selective DNA topoisomerase I poison, NU:UB 235. G. Kay, D.J. Mincher, L. Young, H. Downing, A. Turnbull and M.C. Bibby • European Journal of Cancer Supplements, Volume 2, Issue 8, September 2004, Pages 156-157
  21. US Patent US2003130272 [corresponding to PCT/GB00/04829, WO0144190]. Anthracene derivatives as anti-cancer agents. Inventors: Mincher D.J, Turnbull A, Kay G.G. Publication Date: 10-07-2003.
  22. Design of tumour-activated prodrugs that exploit the dark side of matrix metalloproteinases. Mincher D.J, Turnbull A, Kay G, Di Salvo A, Young L, Bratkova D, Bibby M.C, Double J.A, Lyle J, Loadman P.M. Proceedings of the American Association for Cancer Research, (2003), 44, (2nd ed.), 4627.
  23. Design of tumour-activated prodrugs that harness the 'dark side' of MMP-9. Young L, Di Salvo A, Turnbull A, Lyle J, Bibby M.C, Double J.A, Kay G, Loadman P.M, Mincher DJ, British Journal of Cancer, (2003), 88(Suppl. 1), S27. Winner of the BACR best scientific poster prize at the British Cancer Research Meeting (July) 2003, Bournemouth, UK
  24. New leukaemia-selective dual topoisomerase inhibitors. Mincher D.J, Turnbull A, Kay G, Young L, Bibby M.C, Double J.A, Leukaemia, (2003), 17(3), O38
  25. NU:UB 199: A new colon selective agent that targets topoisomerase I and the beta- isoform of topoisomerase II. Young L, Mincher D.J, Turnbull A, Kay G, Pettersson S, Bibby M.C, Double J.A, British Journal of Cancer, (2002), 86(Suppl. 1), P230.
  26. NU:UB 199, a new dual inhibitor of topoisomerase I and II with selectivity for colon carcinoma. Mincher D.J, Turnbull A, Kay G, Young L, Pettersson S, Bibby M.C, DoubleJA, Proceedings of the American Association for Cancer Research, (2002), 43,1157.
  27. NU:UB 199, a new colon selective agent that targets topoisomerase I and II. Mincher D.J, Turnbull A, Kay G, Young L, Pettersson S, Bibby M.C, Double J.A, Clinical Cancer Research, (2001), 7(11)(Suppl.), 452.
  28. In vitro and in vivo-active anthraquinone peptide conjugates: A putative pharmacophore for colon specificity. Pettersson S, Turnbull A, Kay G, Bibby M.C, Double J.A, Mincher D.J, British Journal of Cancer, (2001), 85, (Suppl. 1),92.
  29. International Patent WO0144190 [corresponding to PCT /GB00/048, CA2395170 (anti-cancer agents III), EP1 244624]. Anthracene derivatives as anti-cancer agents. Inventors: Mincher D.J, Turnbull A, Kay G.G. Publication Date: 21-06-2001.
  30. Design of new topoisomerase I inhibitors: Synthesis and in vitro activity. Mincher D.J, Kay G, Pettersson S, TurnbuII A, Bibby M.C, British Journal of Cancer, (2001), 85, (Suppl. 1),92.
  31. Design of novel inhibitors of human DNA topoisomerase I. Mincher D.J, Kay G, McDonald J.E.L, Turnbull A, Bibby M.C, Double J.A, Clinical Cancer Research, (2000), 6, (Suppl.),136.
  32. Design, synthesis and development of novel inhibitors of human DNA-topoisomerase I. Mincher D.J, Kay G, McDonald J.E.L, Turnbull A, Bibby M.C, Double J.A, British Journal of Cancer, (2000), 83, (Suppl.1), P161.
  33. In vivo anti-tumour activity and preclinical development of spacer-linked anthraquinonyl-amino acid topoisomerase inhibitors. Mincher D.J, Turnbull A, Bibby M.C, Double J.A, Gilmour P.S, Lowe G, Kay G, Hickson I.D, British Journal of Cancer, (1999), 80, (Suppl. 2), P87.

Teaching

Dr Kay is a teaching group leader for chemical sciences. He teaches on a variety of undergraduate and postgraduate modules including:

  • Biomolecular Pharmacy,
  • Medicinal Analysis & Aseptic Control,
  • MPharm Projects,
  • Therapeutic Delivery,
  • Forensic & Analytical Projects,
  • Spectroscopy,
  • Drug Analysis & Toxicology and
  • Project preparation and MSc Research projects.